Public Profile

Protheos

Protheos, a leading player in the biotechnology sector, is headquartered in France and operates extensively across Europe. Founded in 2015, the company has rapidly established itself as a pioneer in the development of innovative biopharmaceutical solutions, focusing on advanced therapies and personalised medicine. Protheos is renowned for its unique approach to drug development, leveraging cutting-edge technologies to enhance therapeutic efficacy and patient outcomes. With a commitment to research and development, the company has achieved significant milestones, including collaborations with major pharmaceutical firms and successful clinical trials. As a trusted name in the industry, Protheos continues to push the boundaries of biotechnology, positioning itself at the forefront of medical advancements and contributing to the evolution of healthcare solutions.

DitchCarbon Score

How does Protheos's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

26

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Protheos's score of 26 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.

40%

Let us know if this data was useful to you

Protheos's reported carbon emissions

Protheos, headquartered in France, currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Consequently, there are no documented reduction targets or climate commitments outlined in their initiatives. Without concrete emissions data or established reduction goals, it is challenging to assess their climate impact or commitments within the industry context. Protheos may still be in the process of developing their sustainability strategies or reporting frameworks.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Protheos's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Protheos is in FR, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Protheos is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Groupe Lépine S.A.

FR
Medical, precision and optical instruments, watches and clocks (33)
Updated 23 days ago

Johnson And Johnson

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Stryker

US
Health and social work services (85)
Updated 11 days ago

Fractyl Health, Inc.

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 23 days ago

Adler Ortho S.p.A.

IT
Medical, precision and optical instruments, watches and clocks (33)
Updated 23 days ago

C2F Implants

FR
Medical, precision and optical instruments, watches and clocks (33)
Updated 23 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers